KIA
VRTX icon

KCM Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

KCM Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24M Buy
2,492
+1,279
+105% +$567K 0.04% 204
2026
Q1 		$542K Buy
1,213
+237
+24% +$111K 0.02% 259
2025
Q4 		$442K Buy
+976
New +$421K 0.01% 285
2014
Q4 		– Sell
-2,789
Closed -$313K – 534
2014
Q3 		$313K Buy
+2,789
New +$266K 0.03% 400

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

KCM Investment Advisors's VRTX Position: Q2 2026 in Review

KCM Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 105% in Q2 2026, buying an estimated $567K and bringing the position to 2,492 shares worth $1.24M. The position accounts for 0.04% of the portfolio, ranked #204.

KCM Investment Advisors first reported a position in VRTX in Q3 2014 and has held it in 4 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • KCM Investment Advisors held 2,492 shares of Vertex Pharmaceuticals worth $1.24M as of Q2 2026.
  • KCM Investment Advisors bought 1,279 Vertex Pharmaceuticals shares in Q2 2026, an estimated $567K.
  • Vertex Pharmaceuticals made up 0.04% of KCM Investment Advisors's portfolio in Q2 2026, its #204 holding.
  • KCM Investment Advisors first reported a position in Vertex Pharmaceuticals in Q3 2014 and has held it in 4 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on KCM Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.